Evidence Table 9a. Efficacy of Pharmacologic Interventions for Behavioral Problems Related to Dementia: Systematic Reviews

AuthorRCT/NIntervention OutcomesResult Quality and Comments
DrugDosePeriod (in weeks)ScaleTrxPlaceboP value NNH
Lanctot et al., 1998122 13 / 295Typical neuroleptic.05–1.2 DDDAt least 4Behavioral improvementPercentage with clinically significant improvement in CGI61%38% P = <.0001 4(3, 7)Good
Treatment vs. placebo difference26%Diagnosis of primary dementia in only 70% of RCTs; all patients had BPRD at baseline; patients not exclusively living at home nor had mild to moderate dementia
Davidson et al., 2000124 3 / 911Atypical neuroleptic--6–12Behavioral (NPI/BEHAVE-AD)Efficacy (clinically significant improvement)OR: 0.59 (95% CI, 044 to 0.78)8 (5, 18)Good
Respiredone/ olanzepineAll patients had BPRD at baseline; mean MMSE <10 (7.3); clinical setting was NHs
Kirchner et al., 2000125 2 / 670Thioridazine--4, 8, 32Behavior (modified Hamilton Anxiety Rating Scale (mHARS))mHARS (anxious mood/ tension/fear/insomnia)OR: 4.9 (95% CI, 3.2 to 7.5)Good
Global (CGE clinical global evaluation impression of change)mHARS (intellect/agitation /depressed mood)OR: 3.6 (95% CI, 2.4 to 5.5)One RCT with 610 patients was conducted at NH; dementia severity not specified

From: Appendix B. Evidence Tables

Cover of Screening for Dementia
Screening for Dementia [Internet].
Systematic Evidence Reviews, No. 20.
Boustani M, Peterson B, Harris R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.